HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.

AbstractPURPOSE:
A major mechanism of resistance to temozolomide involves the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (ATase). The main aims of this phase I trial were to determine an ATase-depleting dose (ADD) of lomeguatrib, a potent pseudosubstrate inhibitor, and to define a suitable dose of temozolomide to be used in combination with lomeguatrib in patients with advanced cancer.
EXPERIMENTAL DESIGN:
Lomeguatrib was administered at dose levels of 10 to 40 mg/m2 days 1 to 5, as a single agent, and also in combination with temozolomide. Once the ADD of lomeguatrib was identified, the dose of temozolomide in combination was increased, in successive patient cohorts, from 50 to 175 mg/m2 on days 1 to 5 of a 28-day cycle to define the maximal tolerated dose and dose-limiting toxicity of the combination.
RESULTS:
Thirty-eight patients with advanced solid tumors were enrolled. More than 95% ATase depletion within 4 hours of the first dose was achieved in peripheral blood mononuclear cells at lomeguatrib doses of > or =10 mg/m2/d i.v. or > or =20 mg/m2/d orally, and tumor biopsies showed > or =92% ATase depletion. At the ADD of lomeguatrib i.v., the maximal tolerated dose of temozolomide in combination was 150 mg/m2 days 1 to 5. The dose limiting toxicity of the combination of lomeguatrib and temozolomide was myelosuppression. The toxicity of lomeguatrib alone was minimal. In 23 patients with measurable disease, one complete response was seen and 12 patients had stable disease for at least 3 months.
CONCLUSION:
This first administration of lomeguatrib to man successfully established an oral ADD of lomeguatrib and identified a combination regimen with temozolomide suitable for future clinical evaluation.
AuthorsMalcolm Ranson, Mark R Middleton, John Bridgewater, Siow Ming Lee, Martin Dawson, Debra Jowle, Gavin Halbert, Sue Waller, Helen McGrath, Lindsey Gumbrell, R Stanley McElhinney, Dorothy Donnelly, T Brian H McMurry, Geoffrey P Margison
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 12 Issue 5 Pg. 1577-84 (Mar 01 2006) ISSN: 1078-0432 [Print] United States
PMID16533784 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Enzyme Inhibitors
  • O(6)-(4-bromothenyl)guanine
  • Guanine
  • Dacarbazine
  • O(6)-Methylguanine-DNA Methyltransferase
  • Adenosine Triphosphatases
  • Temozolomide
Topics
  • Adenosine Triphosphatases (metabolism)
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (pharmacokinetics, therapeutic use)
  • Dacarbazine (administration & dosage, analogs & derivatives)
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors (pharmacokinetics, therapeutic use)
  • Female
  • Guanine (administration & dosage, analogs & derivatives)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis (drug therapy)
  • Neoplasms (drug therapy, enzymology)
  • O(6)-Methylguanine-DNA Methyltransferase (antagonists & inhibitors, metabolism)
  • Safety
  • Temozolomide

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: